Table 2.
Strain | MICs of Clinical Routine Antimicrobial Agents (μg/mL) | ||||||||
---|---|---|---|---|---|---|---|---|---|
IPM | MEM | AMK | CAZ | CIP | LVX | TOB | TZP | FEP | |
TL-2856 | a1 | 0.25 | 1 | 2 | ≤0.125 | 0.25 | 0.5 | 8/4 | 2 |
b8 | 2 | 2 | 2 | ≤0.125 | 0.5 | 0.5 | 4/4 | 2 | |
TL-2862 | a1 | 1 | 2 | 2 | ≤0.125 | 0.5 | 0.5 | 4/4 | 1 |
b8 | 4 | 2 | 2 | ≤0.125 | 0.5 | 0.5 | 4/4 | 2 | |
TL-2870 | a1 | 0.25 | 2 | 2 | ≤0.125 | 0.25 | 1 | 4/4 | 1 |
b16 | 4 | 2 | 2 | ≤0.125 | 0.25 | 1 | 4/4 | 2 | |
TL-2872 | a2 | 1 | 1 | 4 | ≤0.125 | 0.5 | 1 | 8/4 | 4 |
b16 | 8 | 1 | 4 | 0.25 | 0.5 | 1 | 8/4 | 4 | |
TL-2873 | a2 | 1 | 2 | 2 | ≤0.125 | 0.5 | 1 | 8/4 | 4 |
b8 | 4 | 2 | 2 | ≤0.125 | 0.5 | 1 | 8/4 | 4 | |
TL-2877 | a2 | 0.25 | 2 | 2 | ≤0.125 | 0.5 | 1 | 2/4 | 1 |
b16 | 4 | 4 | 2 | ≤0.125 | 0.25 | 1 | 4/4 | 1 | |
TL-2854 | 8 | 4 | 4 | 2 | 0.25 | 1 | 1 | 4/4 | 8 |
TL-2858 | 16 | 4 | 2 | 64 | 0.5 | 2 | 0.5 | ≥128/4 | 32 |
TL-2859 | 16 | 4 | 8 | 2 | 1 | 1 | 32 | 4/4 | 8 |
TL-2878 | 16 | 4 | 2 | 64 | 0.5 | 1 | 0.5 | ≥128/4 | 16 |
TL-2958 | 16 | 4 | 4 | 4 | 0.5 | 1 | 2 | 4/4 | 4 |
TL-2997 | 8 | 4 | 2 | 2 | 0.25 | 0.5 | 1 | 4/4 | 4 |
TL-2874 | 1 | 0.25 | 4 | 2 | 0.25 | 0.5 | 1 | 4/4 | 2 |
TL-2875 | 1 | 0.125 | 2 | 2 | 0.25 | 0.5 | 0.5 | 4/4 | 2 |
TL-2891 | 1 | 0.25 | 4 | 4 | ≤0.125 | 0.5 | 1 | 4/4 | 2 |
TL-2892 | 1 | ≤0.125 | 1 | 1 | ≤0.125 | 0.25 | 0.5 | 2/4 | 1 |
TL-2907 | 1 | 0.125 | 4 | 2 | ≤0.125 | 0.25 | 2 | 4/4 | 2 |
TL-2908 | 1 | 0.5 | 4 | 32 | ≤0.125 | 0.25 | 1 | 128/4 | 2 |
Notes: aSusceptible population; bheteroresistant subpopulation; resistant and susceptible strains were shown in blue shading and gray shading, respectively.
Abbreviations: MEM, meropenem; AMK, amikacin; CAZ, ceftazidime; CIP, ciprofloxacin; LVX, levofloxacin; TOB, tobramycin; TZP, piperacillin/tazobactam; FEP, cefepime.